Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.
Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.
Once Adarza’s products launch in the second quarter of 2019, it will be one of a handful of local life sciences startups to have done so.
RiverVest leads $17 million investment in Adarza, brings on new president